|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2006-9-8
|
|
pubmed:abstractText |
To investigate safety and tolerability and pilot efficacy of repeated single doses of Org39141 in patients with active rheumatoid arthritis (RA). Org 39141 is recombinant human cartilage glycoprotein-39, intended to induce mucosal tolerance upon intranasal administration.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0315-162X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
33
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1726-33
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16960935-Adipokines,
pubmed-meshheading:16960935-Administration, Intranasal,
pubmed-meshheading:16960935-Adult,
pubmed-meshheading:16960935-Anti-Inflammatory Agents, Non-Steroidal,
pubmed-meshheading:16960935-Arthritis, Rheumatoid,
pubmed-meshheading:16960935-Cohort Studies,
pubmed-meshheading:16960935-Dose-Response Relationship, Drug,
pubmed-meshheading:16960935-Double-Blind Method,
pubmed-meshheading:16960935-Female,
pubmed-meshheading:16960935-Glycoproteins,
pubmed-meshheading:16960935-Growth Substances,
pubmed-meshheading:16960935-Humans,
pubmed-meshheading:16960935-Lectins,
pubmed-meshheading:16960935-Male,
pubmed-meshheading:16960935-Placebo Effect,
pubmed-meshheading:16960935-Recombinant Proteins,
pubmed-meshheading:16960935-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Intranasal administration of recombinant human cartilage glycoprotein-39. A phase I escalating cohort study in patients with rheumatoid arthritis.
|
|
pubmed:affiliation |
Department of Rheumatic Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Clinical Trial, Phase I
|
